Baird maintains Tempus AI at Outperform, raises price target to $92 from $85
Baird upgraded Tempus AI to Outperform and raised its price target to $92 from $85, implying 17.2% upside from the Nov 2 close. Recent analyst targets range from $68 to $100.
How this was made

The 30-second read
Why it matters
The price‑target increase may attract short‑term buyers, but without a concrete catalyst the effect could be limited.
Market read
A modest analyst upgrade that could generate brief buying pressure in TPUS.
What to watch
No new earnings or clinical data were released; the upgrade is based on analyst opinion rather than fresh fundamentals.
Background
Tempus AI is a U.S. biotech focused on AI‑driven clinical data platforms. Analyst coverage influences its valuation.
Market effects
May lift sentiment in the biotech sector as analysts signal confidence in AI‑driven health platforms.
Primarily U.S. market impact; limited broader regional effect.
Low global relevance beyond niche biotech investors.
Counterpoint
The target raise could be premature if underlying trial data or revenue growth does not meet expectations.
Key entities
- Analyst FirmBaird
Equity research firm that raised the price target.
- CompanyTempus AI
AI‑focused healthcare data company (NASDAQ: TPUS).

